دورية أكاديمية
Sustained impact of real-time continuous glucose monitoring in adults with type 1 diabetes on insulin pump therapy : results after the 24-month RESCUE study
| العنوان: | Sustained impact of real-time continuous glucose monitoring in adults with type 1 diabetes on insulin pump therapy : results after the 24-month RESCUE study |
|---|---|
| المؤلفون: | Charleer, Sara, de Block, Christophe, Nobels, Frank, Radermecker, Regis P., Lowyck, Ine, Mullens, Annelies, Scarniere, Denis, Spincemaille, Katrien, Strivay, Marie, Weber, Eric, Taes, Youri, Vercammen, Chris, Keymeulen, Bart, Mathieu, Chantal, Gillard, Pieter |
| المساهمون: | RESCUE Trial Investigators |
| المصدر: | 0149-5992 ; Diabetes care |
| سنة النشر: | 2020 |
| المجموعة: | IRUA - Institutional Repository van de Universiteit Antwerpen |
| مصطلحات موضوعية: | Human medicine |
| الوصف: | OBJECTIVE In recent years, a growing number of people with type 1 diabetes gained access to real-time continuous glucose monitoring (rtCGM). Long-term benefits of rtCGM are unclear because of a lack of large studies of long duration. We evaluated whether real-world rtCGM use up to 24 months offered benefits, particularly in those living with impaired awareness of hypoglycemia (IAH). RESEARCH DESIGN AND METHODS This 24-month, prospective, observational cohort study followed 441 adults with insulin pumps receiving full reimbursement for rtCGM. Forty-two percent had IAH. The primary end point was evolution of HbA(1c), with secondary end points change in acute hypoglycemia complications, diabetes-related work absenteeism, and quality of life scores. Additionally, we evaluated whether people could achieve glycemic consensus targets during follow-up. RESULTS After 24 months, HbA(1c) remained significantly lower compared with baseline (7.64% [60 mmol/mol] vs. 7.37% [57 mmol/mol], P < 0.0001). Sustained benefits were also observed for the score on the hypoglycemia fear survey and hypoglycemia-related acute complications irrespective of hypoglycemia awareness level. People with IAH had the strongest improvement, especially for severe hypoglycemia (862 events in the year before vs. 119 events per 100 patient-years in the 2nd year, P < 0.0001). Over 24 months, more people were able to meet hypoglycemia consensus targets at the expense of slightly fewer people achieving hyperglycemia consensus targets. Furthermore, the number of people with HbA(1c) <7% (<53 mmol/mol) without severe hypoglycemia events more than doubled (11.0% vs. 25.4%, P < 0.0001). CONCLUSIONS Use of rtCGM led to sustained improvements in hypoglycemia-related glucose control over 24 months. Lower fear of hypoglycemia, fewer acute hypoglycemia-related events, and fewer diabetes-related days off from work were observed, particularly in those with IAH. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/isi/000590854800026 |
| الإتاحة: | https://doi.org/10.2337/DC20-1531Test https://hdl.handle.net/10067/1744280151162165141Test https://repository.uantwerpen.be/docstore/d:irua:3994Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.95D53B96 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |